Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

View Full Paper
Ask AI
Bookmark
Share

Authors

SRShambavi RichardTGTara GregorySCSaurabh Chhabra

Discussion

Loading...

Member takes

Overview

Preliminary results demonstrate CAR T-cell therapy achieves 100% MRD negativity in relapsed/refractory multiple myeloma, highlighting promising efficacy and safety.

Key Points

  • AZD0120 achieved 100% MRD negativity in patients with relapsed/refractory multiple myeloma, indicating strong efficacy.
  • The median duration for treatment-emergent neurotoxicities was low, with no cases of grade ≥3 events reported.
  • Observational analysis included data from 25 patients across two dose levels of AZD0120 treatment.
  • Findings suggest potential for CAR T-cell therapy to provide effective options for hematologic cancers with lower risks.

Cite This Study

Richard et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd40https://doi.org/10.1182/blood-2025-269
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma2025 · 3 citations
  2. 2ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)2025
  3. 3One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus2025 · 1 citations
  4. 4BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002)2025 · 2 citations
  5. 5A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma2025 · 2 citations